semaj83/ctmatch_classification huggingface dataset:
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Hypertension type 2 diabetes elevated blood pressure and pulse pressure albuminuria  Severe hypertension History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm Liver, kidney (not caused by diabetes), or pancreas disease Type 1 diabetes or uncontrolled type 2 diabetes Allergy to certain medications used to treat high blood pressure Other protocol-defined inclusion/
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Hyperlipidemia TC:220～270mg/dl Male: 40-70 years old/ female: postmenopausal-70 years old <40kg in weight  History of CHD(angina, MI, post-PTCA/CABG, etc.) History of CVA(stroke, TIA, etc.) Underlying malignant tumor
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Atrial Fibrillation Radiofrequency Catheter Ablation Patients requiring MV surgery with at least 6 month history of atrial fibrillation  Patients with sick sinus syndrome Hyperthyroidism Permanent pacemaker Previous cardiac surgery
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 75.0-999.0,  Acute Myocardial Infarction Subjects of 75 or more years of age Diagnosis of AMI: chest pain or any symptom of myocardial ischemia of, at least, 20 minutes of duration, not responding to nitrate therapy, an evolution period of less than 6 hours after symptom onset until randomization process, and, at least, one of the following alterations ST-elevation >=2 mm in 2 or more precordial leads ST-elevation >=1 mm in 2 or more anterior leads Complete de novo (or probably de novo) left bundle branch block (LBBB) Subject should be able to give informed consent prior to randomization process and should agree to fulfill all procedures described in the protocol, including follow-up after hospital discharge. A written consent signed by a close relative with witness is also acceptable  Documented contraindication to the use of fibrinolytics. 1.1. Internal active bleeding or known history of hemorrhagic diathesis 1.2. History of previous CVA of any kind or at any time 1.3. Intracranial tumor, arteriovenous malformation, aneurysm or cerebral aneurysm repair 1.4. Major surgery, parenchymal biopsy, ocular surgery or severe traumatism in the 6 weeks prior to randomization 1.5. Unexplained puncture in a non-compressible vascular location in the last 24 hours prior to randomization 1.6. Confirmed arterial hypertension with a reliable measurement of systolic AP >180 mmHg or diastolic AP >110 mmHg 1.7. Known thrombocytopenia < 100.000 platelets/mL 1.8. Prolonged (>20 minutes) or traumatic cardiopulmonar resuscitation (CPR) in the 2 weeks prior to randomization 1.9. History or signs suggesting aortic dissection Cardiogenic shock Estimated door-to-needle time >120 minutes Administration of fibrinolysis in the 14 days prior to randomization Administration of any glycoprotein IIa/IIIb inhibitor in the 24 hours prior to randomization Administration of any Low Molecular Weight Heparin (LMWH) in the 8 hours prior to randomization Actual oral anticoagulant treatment Suspected AMI secondary to occlusion of one lesion treated previously with a percutaneous coronary intervention (within the previous 30 days for angioplasty or conventional stent and within the previous 12 months for coated stents) Dementia or acute confusional state at the time of randomization Subject incapacity or unwillingness to give informed consent -at least, verbally
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Atrophy Community living Caucasian woman ≥ 65 years; live expectation > 2 years  secondary osteoporosis CVD-events including stroke Participation in other studies Medication with impact on bone during the last 2 years bisphosphonates parathormone strontium HRT, anabolic steroids calcitonin natriumflourides
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypertension Males or females, 18 years of age or older Acute ischemic cerebral stroke (IS) with uncontrollable hypertension that may need to be controlled for the purpose of considering thrombolytic therapy or anticoagulation therapy Intracerebral hemorrhagic (ICH) stroke patients, including subarachnoid hemorrhage (SAH) (surgically treated or not), any territory with an appropriate study (head CT scan or MRI scan) providing results consistent with this diagnosis, who may require the control of hypertension or control of blood pressure  Allergy to Nicardipine or known hypersensitivity to Nicardipine Chronic renal failure or Creatinine blood sample levels> 2.0 Impaired hepatic function defined as a two times value of liver enzymes Severe left ventricular dysfunction defined as ventricular ejection fraction < 30% Patients or authorized representative who refused be enrolled into this study Advanced aortic stenosis Pregnant or nursing women will not be enrolled in this study No patient will be allowed to be enrolled in this study more than once Patients may not be enrolled into other clinical studies during their involvement with this study
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypertension Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 The following patients will be eligible for study participation Patients with either type 1 or type 2 diabetes. Diabetes will be defined as those patients presently taking either oral hypoglycemic agents or insulin therapy (oral hypoglycemic agents to all drugs in the drug classes of: alpha-glucosidase inhibitors, biguanides, meglitinides, sulfonylureas, thiazolidinediones and adjunctive therapy) taken for >6 months to rule-out steroid-induced diabetes and gestational diabetes  Patients will be excluded from the study if they Do not provide or are unable to provide written informed consent Refuse or are unlikely to attend follow-up visits for BP measurements Are institutionalized Are <18 years of age Do not understand English Enrolled in other diabetes or hypertension trials Subjects will be recruited whether or not they are receiving antihypertensive therapy
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Lung Cancer Heart Disease COPD Healthy sedentary smokers (> 4 per day for at least one year) Ages 18 to 65 years Must be able to give informed consent Must live in the area for the next 3 months Willing to use the nicotine patch to attempt smoking cessation Must receive consent to participate from primary care physician  Cannot read or write fluently in the English language Pregnancy or plans to attempt pregnancy minutes or more per week of moderate or vigorous physical activity Smokes cigars, pipes, or uses smokeless tobacco at least once per week Currently in a quit smoking program Currently using NRT of any kind or using any other quit smoking method or treatment Never had an adverse reaction to the nicotine patch resulting in discontinuation of use Poor willingness or inability to comply with protocol requirements An employee of the Centers for Behavioral and Preventive Medicine Previous participant in Commit to Quit or Fit to Quit smoking cessation studies
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Type 2 Diabetes type 2 diabetes managed by diet or metformin only A1c < 8.5%  treated with insulin or oral agents other than metformin in the past 6 months evidence of diabetic complications including coronary artery disease, stroke, transient ischemic attacks, peripheral vascular disease, nephropathy, retinopathy, or neuropathy type 1 diabetes or a history suggestive of a secondary causes of diabetes A1c ≥ 8.5% participated in another clinical trial within the past 30 days
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Type 2 Diabetes Type 2 diabetes > 3 months duration Male or female Over 65 years of age Diet controlled only HgbA1C < 8.5%  Treatment with oral hypoglycemic agents or insulin or the likelihood of requiring treatment with these during the study Anemia hgb below 130 g/L (males) and below 120 g/L (females) Taking medications that known to interfere with glucose metabolism eg systemic corticosteriods, non-selective beta blockers Known or suspected allergy to glyburide, sulfa drugs or GlucoNorm impaired liver function, as shown by but not limited to AST and/or ALT > 2x the upper limit of normal Impaired renal function, as shown by but not limited to serum creatinine > 133 µmol/L (males) or 124 µmol/L (females) Participated in another clinical trial within the past 30 days
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Contrast Induced Nephropathy Subjects age 18 and over and of either gender Scheduled to receive CT scan with intravenous contrast dye Non diabetics or subjects with type 1 or 2 diabetes mellitus Written informed consent Subjects who are on diuretics and non-steroidal inflammatory agents will not be excluded Subjects who have received n-acetylcysteine or sodium bicarbonate pre CT scan will not be excluded  Pregnant or lactating women End-stage renal disease (on hemodialysis or peritoneal dialysis) A known history of acute renal failure Subjects receiving glucophage/metformin or glucovance Subjects who cannot give written informed consent Subjects receiving peritoneal dialysis or hemodialysis Subjects enrolled in another investigational drug study ≤ 30 days of enrollment into the present study Subjects with a known hypersensitivity or anaphylaxis to contrast dye or iodine Subjects with known hypersensitivity or anaphylaxis to erythropoietin, mammalian-cell derived products, or human albumin Age < 18 years
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Seasonal Influenza Vaccine Subjects eligible for enrollment into this study are male and female adults who were ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry available for all the visits scheduled in the study and able to comply with all study requirements in good health as determined by medical history physical examination clinical judgment of the investigator Written informed consent had to be obtained from all the subjects before enrollment in the study after the nature of the study had been explained  Subjects were not to be enrolled into the study if at least one of the following was fulfilled Any serious chronic or acute disease such as Cancer (leukemia, lymphomas, neoplasm), except for benign or localized skin cancer and non-metastatic prostate cancer not presently treated with chemotherapy Congestive heart failure Advanced arteriosclerotic disease Chronic obstructive pulmonary disease (COPD) requiring oxygen therapy and/or acute exacerbation of a COPD within the last 14 days Autoimmune disease (including rheumatoid arthritis), if under immunosuppressive therapy (see below) Insulin dependent diabetes mellitus Acute or progressive hepatic disease Acute or progressive renal disease
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Atrial Fibrillation History of symptomatic, continuous atrial fibrillation defined as: Continuous atrial fibrillation lasting greater than 1 year but less than 4 years or nonself-terminating atrial fibrillation, lasting greater than 7 days but no more than 1 year, with at least one failed direct current cardioversion. A failed cardioversion was defined as an unsuccessful cardioversion or one in which normal sinus rhythm was established but not maintained beyond 7 days Atrial fibrillation symptoms included the following: palpitations, fatigue,exertional dyspnea, exercise intolerance Age between 18 and 70 years Failure of at least one Class I or III rhythm control drug Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study  Structural heart disease of clinical significance including Previous cardiac surgery (excluding coronary artery bypass graft and mitral valve repair) Symptoms of congestive heart failure including, but not limited to, New York Heart Association (NYHA) Class III or IV congestive heart failure and/or documented ejection fraction <40% measured by acceptable cardiac testing Left atrial diameter >55 mm Moderate to severe mitral or aortic valvular heart disease Stable/unstable angina or ongoing myocardial ischemia Myocardial infarction (MI) within 3 months of enrollment Congenital heart disease (not including atrial septal defect or patent foramen ovale without a right to left shunt) where the underlying abnormality increases the risk of an ablative procedure Prior atrial septal defect of patent foramen ovale closure with a device using a percutaneous approach Hypertrophic cardiomyopathy (left ventricular septal wall thickness >1.5 cm)
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Schizophrenia Schizoaffective Disorder Bipolar Disorder Patients must be male or female, age 18-65 Patients must have a definitive diagnosis by DSM-IV of schizophrenia, bipolar or schizoaffective disorder Patients can be receiving inpatient or outpatient treatment at time of enrollment Patients must have been treated with (Mellaril) thioridazine, (Risperdal) risperidone or (Seroquel) quetiapine at least three months at time of enrollment Patients must be able to provide written informed consent  Patients with a primary diagnosis other than schizophrenia, schizoaffective or bipolar disorder Patients who are currently taking other medications that have been shown to prolong the QTC, including tricyclic antidepressants, fluoroquinolones or antiarrythmics Patients unable to provide written informed consent